title: Influence of recombinant interleukin-2 and alpha- and gamma-interferons on the induction of novel class I antigens.
abstract: Previous results obtained in our laboratory showed that novel class I antigens, closely related to HLA-A (TM antigen related to HLA-A9 and GO antigen related to HLA-A24), were expressed on activated HLA-A9 or HLA-A24 peripheral blood lymphocytes (PBL), whatever activation factor was used [mitogenic stimulation (PHA, PWM, Con A), EBV transformation or alloactivation], but not on resting T and B lymphocytes. These antigens were also expressed on HLA-A9 or HLA-A24 common acute lymphoblastic leukaemias (cALL) and some 'immature' chronic lymphocytic leukaemias (B-CLL), but not in hairy cell leukaemias (HCL), most of the B-CLL, acute myeloblastic leukaemias (AML) and acute myelomonoblastic leukaemias (AMoL). In order to investigate the regulation mechanisms of these novel class I antigens, PBL and different leukaemic cell types were treated in vitro with recombinant IL-2 (rIL-2) and alpha and gamma-interferon (rIFN). Our results showed that without previous activation, but after culture with rIL-2, TM and GO antigens could be induced in HLA-A9 or HLA-A24 PBL and enhanced in HLA-A9 or HLA-A24 B-CLL cases, whereas no expression was found in HLA-A9 or HLA-A24 HCL, T-ALL, AML or AMoL. After culture with rINFs, the expression of TM and GO antigens could be induced on HLA-A9 PBL and all HLA-A9 leukaemic cell varieties. Our results support the hypothesis that the expression of class I antigens is induced at an early stage of the cell cycle.
authors.affiliation: Centre Régional de Transfusion Sanguine de Strasbourg, France.
authors.forename: Y
authors.initials: Y
authors.lastname: Mitsuishi
authors.forename: M
authors.initials: M
authors.lastname: Fellous
authors.forename: A
authors.initials: A
authors.lastname: Urlacher
authors.forename: S
authors.initials: S
authors.lastname: Mayer
authors.forename: M M
authors.initials: MM
authors.lastname: Tongio
mesh_terms: D002453:Cell Cycle; D015234:HLA-A Antigens / Q000096:biosynthesis; D059871:HLA-A24 Antigen; D015395:Histocompatibility Antigens Class I / Q000096:biosynthesis*; D006801:Humans; D066298:In Vitro Techniques; D007370:Interferon Type I / Q000494:pharmacology*; D007371:Interferon-gamma / Q000494:pharmacology*; D007376:Interleukin-2 / Q000494:pharmacology*; D007700:Kinetics; D008214:Lymphocytes / Q000187:drug effects / Q000276:immunology; D010835:Phytohemagglutinins / Q000494:pharmacology; D011994:Recombinant Proteins; D014407:Tumor Cells, Cultured / Q000187:drug effects / Q000276:immunology
chemical_list: D015234:HLA-A Antigens; D059871:HLA-A24 Antigen; C037709:HLA-A9 antigen; D015395:Histocompatibility Antigens Class I; D007370:Interferon Type I; D007376:Interleukin-2; D010835:Phytohemagglutinins; D011994:Recombinant Proteins; C028784:phytohemagglutinin-P; D007371:Interferon-gamma